[go: up one dir, main page]

NO20041681L - Substituerte 4-fenyl-4-[1H-imidazol-2-yl]-piperidinderivater for reduksjon av iskemisk skade - Google Patents

Substituerte 4-fenyl-4-[1H-imidazol-2-yl]-piperidinderivater for reduksjon av iskemisk skade

Info

Publication number
NO20041681L
NO20041681L NO20041681A NO20041681A NO20041681L NO 20041681 L NO20041681 L NO 20041681L NO 20041681 A NO20041681 A NO 20041681A NO 20041681 A NO20041681 A NO 20041681A NO 20041681 L NO20041681 L NO 20041681L
Authority
NO
Norway
Prior art keywords
imidazol
phenyl
substituted
ischemic damage
agent
Prior art date
Application number
NO20041681A
Other languages
English (en)
Inventor
Marcel Jan Maria Borgers
Frans Eduard Janssens
Joseph Elisabeth Leenaerts
Francisco Javi Fernandez-Gadea
Theo Frans Meerts
Antonio Gomez-Sanchez
Willem Flameng
Paul Joannes Ludovic Herijgers
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of NO20041681L publication Critical patent/NO20041681L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Den foreliggende oppfinnelse vedrører et middel for å redusere iskemisk skade på et organ, spesielt et hjerte og en hjerne, farmasøytiske sammensetninger omfattende midlet og anvendelsen av midlet for behandlingen av iskemiske sykdommer på hjertet og hjernen. Midlet omfatter et substituert 4-fenyl-4-[IH-imidazol-2-yl]-piperidinderivat ifølge formel (1). Anvendelsen av midlene har viktige kliniske forgreninger med hensyn på reduksjonen av iskemisk skade på et organ i et pattedyr, spesielt et hjerte og/eller en hjerne, forebyggingen av koronararteriesykdommer i et pattedyr ved å indusere en kardiobeskyttende effekt og behandlingen og forebyggingen av slag.
NO20041681A 2001-10-15 2004-04-23 Substituerte 4-fenyl-4-[1H-imidazol-2-yl]-piperidinderivater for reduksjon av iskemisk skade NO20041681L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01203927 2001-10-15
PCT/EP2002/011371 WO2003039440A2 (en) 2001-10-15 2002-10-10 Substituted 4-phenyl-4-(1h-imidazol-2-yl)-piperidine derivatives for reducing ischaemic damage

Publications (1)

Publication Number Publication Date
NO20041681L true NO20041681L (no) 2004-04-23

Family

ID=8181081

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20041681A NO20041681L (no) 2001-10-15 2004-04-23 Substituerte 4-fenyl-4-[1H-imidazol-2-yl]-piperidinderivater for reduksjon av iskemisk skade

Country Status (26)

Country Link
US (1) US7390822B2 (no)
EP (1) EP1438049B1 (no)
JP (1) JP4418676B2 (no)
KR (1) KR100967599B1 (no)
CN (1) CN1283252C (no)
AR (1) AR036800A1 (no)
AT (1) ATE345799T1 (no)
AU (1) AU2002363369B2 (no)
BR (1) BR0213325A (no)
CA (1) CA2462374C (no)
CY (1) CY1106335T1 (no)
DE (1) DE60216310T2 (no)
EA (1) EA007657B1 (no)
ES (1) ES2276980T3 (no)
HR (1) HRP20040325A2 (no)
HU (1) HUP0402332A3 (no)
IL (1) IL161347A0 (no)
MX (1) MXPA04003480A (no)
MY (1) MY139586A (no)
NO (1) NO20041681L (no)
NZ (1) NZ531733A (no)
PL (1) PL370371A1 (no)
PT (1) PT1438049E (no)
UA (1) UA75980C2 (no)
WO (1) WO2003039440A2 (no)
ZA (1) ZA200402816B (no)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200403058A (en) * 2002-04-19 2004-03-01 Bristol Myers Squibb Co Heterocyclo inhibitors of potassium channel function
AR044010A1 (es) * 2003-04-11 2005-08-24 Janssen Pharmaceutica Nv Uso de derivados de 4-fenil-4- [1h-imidazol-2-il]- piperidina sustituidos como agonistas delta opioideos no peptidos selectivos, con actividad antidepresiva y ansiolitica
WO2005005478A2 (en) * 2003-07-02 2005-01-20 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g protein-coupled opioid receptor; delta 1 (oprd1)
WO2005015242A1 (en) * 2003-08-06 2005-02-17 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g protein-coupled opioid receptor kappa 1 (opkr1)
TW200633990A (en) * 2004-11-18 2006-10-01 Takeda Pharmaceuticals Co Amide compound
ATE506359T1 (de) 2007-11-30 2011-05-15 Bayer Schering Pharma Ag Heteroaryl-substituierte piperidine
DE102009014484A1 (de) 2009-03-23 2010-09-30 Bayer Schering Pharma Aktiengesellschaft Substituierte Piperidine
DE102009022896A1 (de) 2009-05-27 2010-12-02 Bayer Schering Pharma Aktiengesellschaft Substituierte Piperidine
DE102009022894A1 (de) 2009-05-27 2010-12-02 Bayer Schering Pharma Aktiengesellschaft Substituierte Piperidine
DE102009056387B9 (de) * 2009-10-30 2020-05-07 Osram Opto Semiconductors Gmbh Kantenemittierender Halbleiterlaser mit einem Phasenstrukturbereich zur Selektion lateraler Lasermoden
KR102697255B1 (ko) 2017-10-19 2024-08-23 데이진 화-마 가부시키가이샤 벤즈이미다졸 유도체 및 이의 용도
CN113209294B (zh) * 2020-02-05 2023-06-13 复旦大学 Dor激动剂在制备对抗肾脏纤维化药物中的应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2213000A1 (en) 1995-03-06 1996-09-12 Interneuron Pharmaceuticals, Inc. Reduction of infarct volume using citicoline
DE69739469D1 (de) 1996-08-23 2009-07-30 Vegenics Ltd Rekombinanter vasculärer Endothelzellen Wachstumsfaktor D (VEGF-D)
EA199900861A1 (ru) 1997-04-25 2000-06-26 Коллатерал Терапьютикс Усеченные белки, родственные фактору роста эндотелия сосудов
US6103722A (en) * 1997-07-23 2000-08-15 The Medical College Of Wisconsin Research Foundation Inc. Ischemic preconditioning
GB2332373A (en) * 1997-12-19 1999-06-23 Merck & Co Inc Treatment of coronary and/or peripheral ischemia using an antithrombotic agent and an angiogenesis promoter
WO2000037470A1 (en) 1998-12-19 2000-06-29 Janssen Pharmaceutica N.V. Antihistaminic spiro compounds
EP1038872A1 (en) * 1999-02-22 2000-09-27 Pfizer Products Inc. 4-Phenyl-4-heteroarylpiperdine derivatives as opioid receptor ligands
US6297256B1 (en) 1999-06-15 2001-10-02 Neurogen Corporation Aryl and heteroaryl substituted pyridino derivatives GABA brain receptor ligands
EA006507B1 (ru) * 2001-10-15 2005-12-29 Янссен Фармацевтика Н.В. Новые замещенные 4-фенил-4-[1h-имидазол-2-ил] пиперидиновые производные и их применение в качестве селективных непептидных агонистов дельта-опиоидов
FR2831166B1 (fr) 2001-10-18 2004-02-27 Sanofi Synthelabo Aralkyl-tetrahydro-pyridines, leur preparation et compositions pharmaceutiques les contenant

Also Published As

Publication number Publication date
HUP0402332A2 (hu) 2005-02-28
KR100967599B1 (ko) 2010-07-05
EP1438049B1 (en) 2006-11-22
AU2002363369B2 (en) 2008-08-21
ATE345799T1 (de) 2006-12-15
WO2003039440A2 (en) 2003-05-15
DE60216310D1 (de) 2007-01-04
AR036800A1 (es) 2004-10-06
CA2462374C (en) 2011-01-18
NZ531733A (en) 2006-04-28
KR20050035120A (ko) 2005-04-15
ZA200402816B (en) 2005-06-29
JP2005507943A (ja) 2005-03-24
MY139586A (en) 2009-10-30
EP1438049A2 (en) 2004-07-21
WO2003039440A3 (en) 2003-12-18
HRP20040325A2 (en) 2005-04-30
EA007657B1 (ru) 2006-12-29
UA75980C2 (en) 2006-06-15
DE60216310T2 (de) 2007-06-21
CN1283252C (zh) 2006-11-08
PT1438049E (pt) 2007-02-28
HK1072562A1 (en) 2005-09-02
IL161347A0 (en) 2004-09-27
CY1106335T1 (el) 2011-10-12
US7390822B2 (en) 2008-06-24
MXPA04003480A (es) 2004-07-30
CA2462374A1 (en) 2003-05-15
ES2276980T3 (es) 2007-07-01
PL370371A1 (en) 2005-05-16
BR0213325A (pt) 2004-10-13
CN1568186A (zh) 2005-01-19
JP4418676B2 (ja) 2010-02-17
HUP0402332A3 (en) 2009-07-28
EA200400547A1 (ru) 2004-10-28
US20050004170A1 (en) 2005-01-06

Similar Documents

Publication Publication Date Title
NO20041681L (no) Substituerte 4-fenyl-4-[1H-imidazol-2-yl]-piperidinderivater for reduksjon av iskemisk skade
NO20060981L (no) Pyridazinderivater og deres anvendelse som terapeutiske midler
NO20045137L (no) Diketohydrazinderivatforbindelser og legemidler inneholdende forbindelser som aktiv ingrediens
WO2001015593A3 (en) Compositions for reducing vascular plaque formation and methods of using same
EP2269610A3 (en) Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
EP2266569A3 (en) Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
TNSN04246A1 (fr) Derives d'heteroarylamides benzocondenses de thienopyridines utiles comme agents therapeutiques, compositions pharmaceutiques les contenant et methodes pour leur utilisation
IL173032A0 (en) Pyridazine derivatives and their use as therapeutic agents
TW200736252A (en) Novel heteroaryl substituted benzothiazoles
NO20062928L (no) Azabenzofuran substituerte tiourear som inhibitorer av viral replikasjon
EP1014996A4 (en) PREPARATION OF SACCHARIDES AND METHODS FOR TREATING ALZHEIMER'S DISEASE AND OTHER AMYLOIDOSES
PT1213296E (pt) Derivados de glucopiranosiloxipirazole composicoes medicas que os contem e intermediarios na sua producao
BRPI0515483A (pt) derivados heterocìclicos para o tratamento de doenças mediadas por enzimas estearoil-coa desaturase
DE60316779D1 (de) Thiadiazolylpiperazinderivate geeignet für die behandlung bzw. prävention von schmerzen
MXPA05008172A (es) Derivados de malonamida como inhibidores gamma-secretasa.
MXPA04000328A (es) Derivados de alfa-hidroxiamida estatina para tratamiento de enfermedad de alzheimer.
ATE541854T1 (de) Pyrazolderivat, arzneimittelzusammensetzung, die dieses enthält, und zwischenprodukt für dessen herstellung
EP0444196A4 (en) Agent for treatment and prophylaxis of ischemic disease of heart or brain
DE60135108D1 (de) Dermale zusammenstellungen die als wirkstoff coenzym q enthalten
DK1392329T3 (da) Anvendelse af sulodexid til behandling af inflammatorisk tarmsygdom
AR034343A1 (es) Combinaciones farmaceuticas
DE602004007268D1 (de) CYCLOALKYLSULFANYL-SUBSTITUIERTE BENZOiBöTHIOPHENE ALS THERAPEUTISCHE MITTEL
MY147347A (en) Novel 2-heteroaryl substituted benzothiophenes and benzofuranes
ATE366107T1 (de) Verwendung von sulfodehydroabietinsäure zur behandlung entzündlicher darmerkrankungen
NO20050573L (no) 4-'7-halo-2-quino (XA) linyloksy ! fenoksypropionsyrederivater som antineoplastiske midler

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application